January 30, 2025
Danish Biotech Startup Commit Biologics Secures €5.5M Seed Extension to Advance Cancer Immunotherapy
Aarhus, Denmark—
Commit Biologics, developing a novel immunotherapy platform for cancer treatment, has secured €5.5 million in a seed extension round. Announced on January 28, 2025, The latest investment was led by Korys, a new investor, joining existing backers Novo Holdings and Bioqube Ventures. This latest funding brings Commit’s total seed financing to €21.5 million and will help advance its novel BiCE™ platform towards drug candidate selection.
About Commit Biologics
Commit Biologics, founded in 2021 by Nick Stub Laursen, Dennis V. Pedersen, Mikael Winkler, Heidi Gytz Olesen, Kevin Hollevoet, is pioneering the activation of the complement system to treat cancer and autoimmune diseases. The company’s proprietary Bispecific Complement Engaging (BiCE™) platform leverages single-domain antibodies to target and activate the complement protein C1q, enabling a highly selective immune response against tumor cells and cells implicated in autoimmune disorders.
Purpose of financing
The new funds will be used to further develop the BiCE platform and advance towards drug candidate selection. The financing extends Commit’s operational runway into late 2026, supporting ongoing research and development efforts.
CEO's Insights
To strengthen its leadership, Commit has appointed its Chief Scientific Officer, Dr. Mikkel Wandahl Pedersen, as Interim CEO. Dr. Pedersen, an experienced executive with over 20 years in immuno-oncology and autoimmune disease drug development, previously held leadership roles at Nykode Therapeutics and Symphogen. He will continue to oversee the scientific direction of the company while leading its strategic growth.
Dr. Mikkel Wandahl Pedersen, Interim CEO and CSO of Commit Biologics, commented: “This additional financing from Korys underscores the great potential of our BiCE platform to redefine the treatment of cancer and autoimmune disease. We welcome Eva to our Board of Directors, where her expertise will be invaluable as we work towards drug candidate selection. The additional financing further extends our cash runway into late 2026, and we remain hyper-focused on progressing our platform to the next stage of development.”
Investor Perspective
Eva Van Overmeire, Senior Investment Manager at Korys, expressed confidence in Commit’s vision:
"Commit is developing a unique technology that robustly activates the complement system and integrates seamlessly with antibody-based therapies. We believe their innovative approach can make a real difference for patients battling cancer and autoimmune diseases."
Conclusion
With this latest investment, Commit Biologics is well-positioned to accelerate its mission of developing groundbreaking immunotherapies that leverage the complement system, bringing novel treatments closer to patients in need.
For more information, visit Commit Biologics on LinkedIn.